Additional file 1: of Support for phosphoinositol 3 kinase and mTOR inhibitors as treatment for lupus using in-silico drug-repurposing analysis

presents information about quality control of the data, SLE signatures, and significant results obtained: Sheet 1 shows information about datasets including their GEO identifiers, the SLE state, the cell type, and the microarray platform for each, number of control and case samples, PubMed identifier, and date of publication; Sheet 2 shows results of the quality control based on the percentage of missing values and the number of significant genes in each dataset of SLE; Sheet 3 shows the signatures of each dataset used to query on Lincscloud, significant genes sorted by fold change in each signature; and Sheet 4 shows the lists of drugs and knock-in and knockdown genes with similarity scores, median of similarity scores across datasets, and significance values (XLSX 182 kb)

本数据集涵盖数据质控、系统性红斑狼疮（SLE）特征基因集，以及所获显著结果相关信息：工作表1收录各数据集的相关信息，具体包括各数据集的GEO标识符、SLE患病状态、细胞类型、微阵列（microarray）平台、对照样本与病例样本的数量、PubMed文献标识符，以及发表日期；工作表2展示针对各SLE数据集，基于缺失值占比与显著基因数量计算得到的质控结果；工作表3展示用于在Lincscloud中进行检索的各数据集特征基因集，以及各特征基因集中按折叠变化（fold change）排序的显著基因；工作表4收录药物、基因敲入（knock-in）与基因敲低（knockdown）基因列表，及其相似性得分、各数据集间相似性得分的中位数，以及显著性数值（文件为182 KB的XLSX格式）